Sandoz Partners With MAbxience On Emicizumab Biosimilar; Pipeline Reaches 40 Assets
(RTTNews) - Sandoz Group AG (SDZ.SW, SDZNY), a pharmaceutical company focused on affordable medicines, on Friday announced a collaboration with mAbxience for a proposed emicizumab biosimilar.